Global Joint Pain Injection Market (2021 to 2028) - COVID-19 Impact and Analysis - ResearchAndMarkets.com

·3 min read

The "Joint Pain Injection Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Drug, Joint Type, and Distribution Channel" report has been added to ResearchAndMarkets.com's offering.

The joint pain injection market is expected to reach US$ 6,996.88 million in 2028 from US$ 3,667.45 million in 2020; it is estimated to grow at a CAGR of 8.5% from 2021 to 2028.

The growth of the market is mainly attributed to the high prevalence of musculoskeletal disorders and increasing number of sports injuries. However, the high costs of joint repair therapies hinder the market growth.

Hyaluronic acid injections are usually administered for treating sports injuries, as they aid in pain relief, reduce inflammation, and improve joint function. Corticosteroids are also used to treat sports-related injuries. Sports injuries are caused due to direct impact or due to the application of force that is larger than the body part can withstand. The most common sport injuries are sprains, strains, joint injuries, and bruises. As per the National Safety Council (NSC), in 2019, exercise accounted for ~468,000 injuries in the US, the most of any category of sports and recreation. People involved in football, bicycling, basketball, playground, and soccer activities contributed to the highest number of emergency department (ED) visits in that year. It also states sport injuries affect over thousands of youth population engaged in various sports. Further, according to a research from the Australian Institute of Health and Welfare, ~60,000 people were hospitalized due to sports injuries in 2016-2017. Additionally, according to the European Injury Data Base (IDB) sports, annually ~4.5 million people aged 15 years and above approach EU hospitals for the treatment of sport injuries. Thus, the growing number of sport injuries is boosting the demand for joint pain injections.

Based on joint type, the joint pain injection market is segmented into knee, shoulder and elbow, hip, foot and ankle, and others. In 2020, the knee joint type segment accounted for the largest share of the market. Growth of this segment is attributed to the increasing prevalence of knee injuries. For instance, according to a study published in the Journal of Osteoarthritis and Cartilage in 2020, ~303 million people across the world suffer from osteoarthritis, and ~60.0% of this population suffers from knee pain. Furthermore, growing number of product launches for knee pain treatment are also driving the growth of the market for the knee segment.

Reasons to Buy

  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the joint pain injection market.

  • Highlights key business priorities in order to assist companies to realign their business strategies.

  • The key findings and recommendations highlight crucial progressive industry trends in the global joint pain injection market, thereby allowing players across the value chain to develop effective long-term strategies.

  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.

  • Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.

  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

Market Dynamics

Drivers

  • High Prevalence of Musculoskeletal Disorders

  • Increasing Number of Sports Injuries

Restraints

  • High Costs of Joint Repair Therapies

Opportunities

  • Proliferation of Pharmaceutical Sector in Emerging Markets

Future Trends

  • Product Innovations

Companies Mentioned

  • Chugai Pharmaceutical Co., Ltd.

  • Bioventus Inc.

  • Fidia Pharma USA Inc.

  • Flexion Therapeutics, Inc.

  • SEIKAGAKU CORPORATION

  • Ferring B.V.

  • Sanofi

  • Anika Therapeutics, Inc.

  • Teva Pharmaceutical

  • OrthogenRx, Inc.

For more information about this report visit https://www.researchandmarkets.com/r/7s22sj

View source version on businesswire.com: https://www.businesswire.com/news/home/20210514005456/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting